Bluejay Diagnostics Completes SYMON-II Enrollment Ahead of Schedule — Bluejay Diagnostics, Inc.

Event summary

Bluejay Diagnostics completed enrollment of 750 patients in the SYMON-II study, ahead of schedule.
The study evaluates the Symphony™ IL-6 test for assessing 28-day mortality risk in sepsis patients.
Preliminary data shows a 17% 28-day mortality rate among enrolled patients.
Results will support future regulatory submissions and commercialization efforts.

The big picture

Bluejay Diagnostics' completion of SYMON-II enrollment marks a critical step in validating its Symphony™ IL-6 test for sepsis risk assessment. The study's robust dataset positions Bluejay to address a significant unmet need in critical care diagnostics, where rapid, near-patient testing could improve patient outcomes and streamline clinical decision-making. Success here would strengthen Bluejay’s regulatory strategy and market positioning in the competitive diagnostics space.

What we're watching

Regulatory Pathway: Whether the SYMON-II data will support a successful 510(k) application to the FDA.
Clinical Utility: How the Symphony™ IL-6 test integrates into existing clinical workflows for sepsis management.
Market Adoption: The pace at which Bluejay can commercialize the Symphony™ platform post-regulatory approval.